PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma - Trial NCT04040491
Access comprehensive clinical trial information for NCT04040491 through Pure Global AI's free database. This Phase 4 trial is sponsored by Mingzhi Zhang and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
Interventional
drug
Sponsor & Location
Mingzhi Zhang
Zhengzhou University
Timeline & Enrollment
Phase 4
Sep 01, 2019
Sep 01, 2021
Primary Outcome
Overall Response Rate,Progression-free Survival,Overall Survival
Summary
To observe the safety, tolerability and clinical effects of PD-1, chidamide, lenalidomide and
 gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell
 lymphoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04040491
Non-Device Trial